News Archive

JUNO THERAPEUTICS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING, INCLUDING FULL EXERCISE OF UNDERWRITERS’ OPTION TO PURCHASE ADDITIONAL SHARES

By | News, Press Release

Seattle (Dec. 23, 2014) – Juno Therapeutics, Inc. (NASDAQ: JUNO) today announced the closing of its initial public offering of 12.7 million shares of common stock at a price to the public of $24.00 per share, which includes the exercise in full by the underwriters of the offering of their option to purchase 1.7 million shares.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.

Copies of the final prospectus relating to this offering may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by calling toll-free (866) 471-2526, or by e-mailing prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on December 18, 2014. Copies of the registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Juno 

Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Investor Relations Contact:

David Walsey, W2O Group

dwalsey@w2ogroup.com, 858-617-0772

Media Contact:

Andreas Marathovouniotis, W2O Group

amarathis@w2ogroup.com, 212-301-7174

JUNO THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

By | News, Press Release

JUNO THERAPEUTICS ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING

Seattle (Dec. 18, 2014) – Juno Therapeutics, Inc. today announced the pricing of its initial public offering of 11,022,917 shares of common stock at a price to the public of $24.00 per share.  In addition, Juno Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,653,437 shares of common stock to cover over-allotments, if any. Juno Therapeutics’ common stock is expected to begin trading on The NASDAQ Global Select Market under the symbol “JUNO” on December 19, 2014. The offering is expected to close on December 23, 2014, subject to customary closing conditions.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. are acting as lead book-running managers for the offering. Leerink Partners LLC is acting as a co-manager.

The offering is being made only by means of a prospectus, copies of which may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by calling toll-free (866) 471-2526, or by e-mailing prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission on December 18, 2014. Copies of the registration statement, as amended, can be accessed through the SEC’s website at www.sec.gov.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Juno

Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Investor Relations Contact:

David Walsey, W2O Group

dwalsey@w2ogroup.com, 858-617-0772

Media Contact:

Andreas Marathovouniotis, W2O Group

amarathis@w2ogroup.com, 212-301-7174

JUNO’S CAR T AND TCR INVESTIGATIONAL PRODUCT CANDIDATES DEMONSTRATE PROMISING OUTCOMES IN CLINICAL TRIALS IN PATIENTS WITH B-CELL CANCERS

By | News, Press Release

-Data Presented at 56th American Society of Hematology (ASH) Annual Meeting-

SEATTLE (Dec. 8, 2014) – Juno Therapeutics, Inc. announced today that clinical data from its most advanced chimeric antigen receptor (CAR) product candidates, JCAR017, JCAR015 and JCAR014, demonstrated encouraging evidence of clinical responses in acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL). Clinical results were presented in oral and poster presentations at the 56th American Society of Hematology (ASH) Annual Meeting in San Francisco, California.

Highlights from the research include:

  • High rates of tumor reduction in B-cell malignancies, including complete remission rate of 89% in adult relapsed/refractory B-cell ALL with JCAR015.
  • Robust T cell expansion and persistence and clinical remissions with JCAR017.
  • Potential for prolonged T cell persistence with WT-1, a high-affinity T cell receptor (TCR) candidate, in acute myeloid leukemia (AML).
  • Association of cell expansion and persistence with clinical outcome.

“The tumor response rates and duration observed in these ongoing studies remain encouraging as we advance our lead product candidates in hematological malignancies,” said Juno CEO, Hans Bishop.

1.  In an oral presentation on the Phase I clinical trial results of JCAR015 in adults with ALL, Jae H. Park, M.D. of the Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, in New York City, presented:

  • Complete remission occurred in 24/27 (89%) evaluable patients and complete molecular remission occurred in 21/24 (88%) evaluable patients with relapsed/refractory adult ALL.
  • In this ongoing trial, median overall survival was 8.5 months. Durable responses were observed in patients with and without subsequent allogeneic stem cell transplant.
  • Cytokine release syndrome (CRS) requiring vasopressors and/or mechanical ventilation was required for 5/15 patients with morphologic disease, or greater than 5% blasts in the bone marrow, and 0/13 patients without morphologic disease. Grade 3/4 neurotoxicity occurred in 7/28 patients and was generally reversible.

2. In an oral presentation on the Phase I clinical trials results of JCAR015 in patients with B-cell NHL, Craig S. Sauter, M.D., of the Department of Medicine, Memorial Sloan Kettering Cancer Center, presented:

  • At a median follow-up of 9 months (range 1-17.5), 6/6 (100%) patients with poor-risk, relapsed/refractory aggressive B cell NHL remain alive and in remission after treatment with high dose chemotherapy and autologous stem cell transplantation, followed by CD19-directed CAR T cell therapy. Two patients remain alive more than one year from treatment.
  • One patient treated with 1 x107 CAR T/kg experienced severe CRS.

3. In a poster presentation on the Phase I clinical trials results of JCAR017 in pediatric patients with ALL, Rebecca A. Gardner, M.D., of Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, in Seattle, presented:

  • Eleven of 13 (85%) patients with relapsed/refractory ALL following allogeneic stem cell transplantation obtained or maintained an MRD negative complete remission following CAR T cell therapy.
  • All 11 responding patients exhibited in vivo expansion of CAR T cells (median peak CAR+ T cells of 478/uL [range 63-1288] occurring 7‐14 days post infusion), with 6/8 (75.0%) of evaluable patients having CAR T cell persistence of more than 40 days.
  • Two patients received treatment with steroids and tocilizumab for severe cytokine release syndrome. One of these patients experienced grade 4 encephalopathy and there was an additional patient that experienced grade 3 encephalopathy.

4. In an oral presentation on the Phase I clinical trials results of JCAR014 in patients with relapsed/refractory ALL, NHL and chronic lymphocytic leukemia (CLL), Cameron J. Turtle, MBBS, Ph.D., of the Clinical Research Division, Fred Hutchinson Cancer Research Center, in Seattle, presented:

  • In patients receiving defined composition products, responses were observed in 6/10 (60%) evaluable NHL patients, and 2/2 evaluable CLL patients, complete remission occurred in 11/11 (100%) patients and complete molecular remissions occurred in 9/11 (82%) patients with ALL.
  • A subset of NHL patients tested in whom CAR‐T cells became undetectable developed a T cell immune response to sequences in the murine CD19‐specific single-chain variable fragment (scFv) component of the CAR transgene.
  • Severe CRS was observed in 3/13 (23%) ALL patients, including one death, and in 0/14 evaluable NHL/CLL patients. Grade 3 delirium was observed in one patient with CLL.

5. In a poster presentation on the Phase I/II clinical trial results of WT-1 in post-transplant patients with AML, Merav Bar, M.D., of the Fred Hutchinson Cancer Research Center, presented:

  • Escalating doses of donor-derived virus specific CD8+ T cells transduced to express a high-affinity TCR specific for the HLA A*02:01-restricted WT1126-134 (RMFPNAPYL) epitope were administered in high-risk AML patients after allogeneic hematopoietic stem cell transplantation.
  • WT-1 specific T cell delivery was generally well tolerated.
  • 13/15 patients remain alive with follow-up for up to 18 months.
  • 12/15 have ongoing detectable WT-1 cells with follow up ranging from 5 to 368 days from the last infusion.

###

About Juno’s Chimeric Antigen Receptor and High-affinity T Cell Receptor Platform

Juno is developing cell-based immunotherapies based on its chimeric antigen receptor, or CAR, and high-affinity T cell receptor, or TCR, platform to genetically engineer T cells to recognize and kill cancer cells. T cells are a type of white blood cells that identify and kill infected or abnormal cells, including cancer cells, in healthy individuals. Juno leverages its CAR and TCR platform to activate a patient’s own T cells so that they attack cancer cells. Through genetic engineering, a gene is inserted for a particular CAR or TCR construct into the T cell enabling it to better recognize cancer cells. The CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas the TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. CAR constructs typically use a single chain variable fragment, or scFv, to recognize a protein of interest.  The modified T cells can be infused into the patient or frozen and stored for later infusion.

About Juno 

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from some of the world’s leading research institutions, including the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

www.JunoTherapeutics.com

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, the safety and efficacy of our product candidates as well as their potential, and the encouraging nature of clinical data observed to date. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements, amongst others. These forward-looking statements speak only as of the date hereof. Juno Therapeutics disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:

David Walsey, W2O Group

dwalsey@w2ogroup.com, 858-617-0772

Media Contact:

Andreas Marathovouniotis, W2O Group

amarathis@w2ogroup.com, 212-301-7174

JUNO THERAPEUTICS EXECUTES LICENSE FOR PHASE I CAR T PRODUCT CANDIDATE TARGETING CD22 FOR HEMATOLOGICAL MALIGNANCIES

By | News, Press Release

National Cancer Institute Developed Product Candidate to Expand Breadth and Depth of Juno’s Pipeline with Fully Human scFv CAR T Cell Product Candidate Targeting CD22

SEATTLE (Dec. 5, 2014) – Juno Therapeutics, Inc. today announced that it has entered into an agreement to obtain a license from Opus Bio, Inc. for a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio. The NCI has begun enrollment in a Phase I trial evaluating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin’s lymphoma (NHL).

“This fully-human CD22 directed product candidate complements our existing CD19 directed portfolio, representing another important opportunity to investigate an immunotherapy addressing B cell malignancies,” said Juno CEO, Hans Bishop.

The NCI-sponsored trial is designed to enroll patients with CD22 positive cancers, with both CD19 positive and CD19 negative patients eligible for treatment.

CAR T cell therapy has the potential to address an important unmet need, according to Crystal Mackall, M.D., Chief, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health. There is still much to learn about these immunotherapies, but the early results are hopeful.

Financial terms were not disclosed. The license will not become effective until certain closing conditions are satisfied, including obtaining consent from the NCI.
About Juno’s Chimeric Antigen Receptor and High-affinity T Cell Receptor Platform
Juno is developing cell-based immunotherapies based on its chimeric antigen receptor, or CAR, and high-affinity T cell receptor, or TCR, platform to genetically engineer T cells to recognize and kill cancer cells. T cells are a type of white blood cell that identify and kill infected or abnormal cells, including cancer cells, in healthy individuals. Juno leverages its CAR and TCR platform to activate a patient’s own T cells so that they attack cancer cells. Through genetic engineering, a gene is inserted for a particular CAR or TCR construct into the T cell enabling it to better recognize cancer cells. The CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas the TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell. CAR construct typically uses a single chain variable fragment, or scFv, to recognize a protein of interest. The modified T cells can be infused into the patient or frozen and stored for later infusion.

About Juno
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from three of the world’s leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

www.JunoTherapeutics.com

About Opus Bio

Opus Bio (formerly Lentigen Corporation) is a diversified biologics company focused on the development and commercialization of breakthrough treatments for human disease. Lentiviral vectors (LV), the company’s technology platform, are widely recognized by the scientific community as the most efficient method for delivery of genetic sequence information into cells to reprogram their function. The ability to efficiently and stably reprogram mammalian cells has numerous uses in biotechnology and biomedicine, including drug discovery, target validation, biologics manufacturing and cellular therapies.

http://www.biomarkcapital.com/opus-bio

Forward Looking Statements
This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, the potential for immunotherapy to address unmet needs, and effectiveness of the license agreement with Opus Bio. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; risks of increased regulatory requirements; and the satisfaction of conditions to the effectiveness of the license agreements, some of which are beyond the control of Juno and Opus Bio; amongst others. These forward-looking statements speak only as of the date hereof. Juno Therapeutics disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:
David Walsey, W2O Group
dwalsey@w2ogroup.com, 858-617-0772

Media Contact:
Andreas Marathovouniotis, W2O Group
amarathis@w2ogroup.com, 212-301-7174

# # #

JUNO APPOINTS JEFFREY BLUESTONE AS SCIENTIFIC ADVISOR

By | News, Press Release

SEATTLE (December 1, 2014) – Juno Therapeutics today announced the appointment of Jeffrey Bluestone, PhD, as scientific advisor. He will advise the company on T cell therapies, including potential applications in autoimmune disease and organ transplantation.

“We are delighted to have the opportunity to work with Dr. Bluestone, one of the world’s outstanding T cell biologists, who has made major contributions in basic immunology and in the translation of those discoveries to clinical trials,” said Juno CEO Hans Bishop.

Bluestone’s scientific work includes building a broad understanding of human immune responses at the molecular level, with significant contributions to stem cell research and immunology. He has published more than 400 peer-reviewed publications in journals including Nature, Nature Immunology, the Journal of Immunology, and Diabetes.

“I am excited to be working with Juno’s outstanding scientific founders and team to translate discoveries in immune tolerance into medical applications,” said Bluestone.

Bluestone is the A.W. and Mary Margaret Clausen Distinguished Professor and Director of the Hormone Research Institute at the University of California San Francisco, where he guides the institute’s autoimmunity research and clinical initiatives in immune tolerance and T cell therapies. He has held appointments at the University of Chicago and the National Cancer Institute, and is a member of the American Academy of Arts and Sciences and the Institute of Medicine. After earning his BS in biology and MS in microbiology from Rutgers University, Bluestone earned a PhD in immunology from the Cornell Graduate School of Medical Science.

###
About Juno

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from three of the world’s leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

www.JunoTherapeutics.com

Contact:Morgan Warners, The Glover Park Group
mwarners@gpg.com, 202-295-0124

JUNO APPOINTS MAGGIE WILDEROTTER TO BOARD OF DIRECTORS

By | News, Press Release

SEATTLE (November 25, 2014) – Juno Therapeutics today announced that Maggie Wilderotter, Chairman and CEO of Frontier Communications Corporation, has been appointed to the Juno Board of Directors.

Wilderotter, the eighth member of Juno’s Board of Directors, brings significant public company experience as both a board member and a senior executive to the Juno Board. Before joining Frontier Communications in 2004, Wilderotter was Senior Vice President of Worldwide Public Sector at Microsoft. She has also held senior positions with Wink Communications, AT&T, and McCaw Cellular Communications. She serves on the boards of Xerox Corporation, Procter & Gamble Company, and a number of non-profit organizations.

“Maggie’s management acumen and distinguished Board service make her a widely respected adviser, and we are delighted she is bringing her wise counsel to Juno’s Board,” said Juno CEO Hans Bishop.

Among other accolades, from 2009 through 2013 Wilderotter was ranked by FORTUNE magazine as one of the “50 Most Powerful Women in Business” and the Financial Times in 2011 named Wilderotter one of “The Top 50 Women in World Business.”

“I look forward to working with Juno’s board and management team to build on the company’s successful first year. The scientific discovery Juno is engaged in combined with a first class strategy to bring forward game changing therapies makes this a company I am privileged to be associated with,” said Wilderotter.

Mrs. Wilderotter holds a bachelor’s degree in economics from the College of the Holy Cross and was awarded an Honorary Doctor of Engineering degree, honoris causa, from the Stevens Institute of Technology.

 

###

 

About Juno

 

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from three of the world’s leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

 

www.JunoTherapeutics.com

 

Contact: Morgan Warners, The Glover Park Group 

mwarners@gpg.com, 202-295-0124

JUNO T CELL THERAPY FOR LEUKEMIA GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION

By | News, Press Release

SEATTLE (November 24, 2014) – Juno Therapeutics today announced that the FDA has granted Breakthrough Therapy Designation to the company’s JCAR015 chimeric antigen receptor product candidate. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia and was filed by Juno’s collaboration partner, Memorial Sloan Kettering Cancer Center, where Phase 1 clinical trials are currently underway.

 

“The FDA’s action is important news for patients who may benefit from the accelerated development of JCAR015 and is an important moment for the field of cancer immunotherapy, which has the potential to meet the need for more effective treatments in a range of cancers,” said Juno CEO Hans Bishop.

 

The FDA’s Breakthrough Therapy Designation was created to help accelerate the development and review of new drugs for serious or life-threatening conditions. The designation comes with potential benefits, including intensive FDA guidance and eligibility for priority review. It is granted to applicants when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinical endpoints.

 

All three of Juno’s CAR T cell product candidates currently in clinical trials, including JCAR015, are based on chimeric antigen receptor technology that employs the body’s immune system to attack cancer cells. JCAR017 is being tested at Seattle Children’s Hospital for relapsed/refractory CD19-positive pediatric leukemia. JCAR014 is being tested for refractory chronic lymphocytic leukemia, non-Hodgkin’s lymphoma and acute lymphoblastic leukemia at the Fred Hutchinson Cancer Research Center in Seattle, WA. Data on these programs will be presented at the 56th Annual Meeting of the American Society of Hematology meeting next week in San Francisco.

 

###

About Juno

 

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Several product candidates have shown compelling evidence of tumor shrinkage in the clinical trials in refractory leukemia and lymphoma conducted to date. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from three of the world’s leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

 

 

www.JunoTherapeutics.com

 

Forward Looking Statements

 

This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, the possible impact of accelerated approval on patients, the potential for immunotherapy to treat a range of cancers, and the presentation of data at a future meeting of the American Society of Hematology. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements; amongst others. These forward-looking statements speak only as of the date hereof. Juno Therapeutics disclaims any obligation to update these forward-looking statements.

 

 

Contact: Morgan Warners, The Glover Park Group 

mwarners@gpg.com, 202-295-0124

JUNO’S JCAR015 LEUKEMIA T CELL THERAPY GRANTED ORPHAN DRUG DESIGNATION BY FDA

By | News, Press Release

SEATTLE (November 18, 2014) – Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia. JCAR015 Phase I trials are currently underway at Juno’s collaboration partner, Memorial Sloan Kettering Cancer Center.

Orphan drug designations are granted to drugs intended to treat rare diseases or conditions, or “orphan” diseases. The designation allows for incentives to advance development and for marketing of drugs that progress to approval.

All three of Juno’s CAR T cell product candidates currently in trial, including JCAR015, are based on chimeric antigen receptor technology that employs the body’s immune system to attack cancer cells. JCAR017, in Phase I/II trials at Seattle Children’s Hospital, is being tested for pediatric and young adult relapsed/refractory CD19 positive leukemia. JCAR014, currently in Phase I/II trials at the Fred Hutchison Cancer Research Center, is being tested for relapsed or refractory chronic lymphocytic leukemia, non-Hodgkin’s lymphoma, and acute lymphoblastic leukemia.

 

###

About Juno

 

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors.  Juno has shown compelling evidence of tumor shrinkage in clinical trials using multiple cell-based product candidates to address refractory B cell lymphomas and leukemias. The company’s long-term aim is to improve and leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.  Juno brings together innovative technologies from three of the world’s leading research institutions – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

 

Forward Looking Statements

This press release contains forward-looking statements, including statements regarding the clinical development of our product candidates, the impact of the Orphan Drug Designation on the advancement and marketing of JCAR015, and the potential for immunotherapy to treat cancer and other indications. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with the success, cost and timing of our product development activities and clinical trials; the approval and commercialization of our product candidates; and risks of increased regulatory requirements; amongst others. These forward-looking statements speak only as of the date hereof. Juno Therapeutics disclaims any obligation to update these forward-looking statements.

 

www.JunoTherapeutics.com

 

Contact:         Alissa Brenner, The Glover Park Group     

abrenner@gpg.com, 202-295-0121

JUNO THERAPEUTICS FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING

By | News, Press Release

Seattle, Washington, November 17, 2014 /PRNewswire/ — Juno Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. Juno intends to apply to list its common stock under the symbol “JUNO” on The NASDAQ Global Select Market.

Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, and Goldman, Sachs & Co. will act as lead book-running managers for the offering. Leerink Partners LLC will act as a co-manager.

This offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; and Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by calling toll-free (866) 471-2526, or by e-mailing prospectus-ny@ny.email.gs.com.

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

### About Juno

Juno Therapeutics, Inc. is a biopharmaceutical company developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Contact: Alissa Brenner, The Glover Park Group

abrenner@gpg.com, 202-295-0121

Juno Appoints Hal Barron, M.D. to Board of Directors

By | News, Press Release

Juno Therapeutics, Inc. today announced the appointment of Hal Barron, M.D., President of Research & Development at Calico, to its Board of Directors

“Hal is one of the most respected clinician-scientists and successful drug developers in the biotechnology industry. His unique perspective and experiences at Genentech and Roche, particularly in oncology, will bring valuable insights to our team as we work to bring our CAR and TCR product candidates to patients and disrupt the treatment of cancer,” said Juno CEO Hans Bishop.

Dr. Barron is currently President of Research & Development at Calico (California Life Sciences LLC), a Google-founded research and development company. Previously, he served as Executive Vice President and Chief Medical Officer at Genentech and Roche. He received his bachelor’s degree from Washington University in St. Louis, his medical degree from Yale University, and completed his training in medicine and cardiology at the University of California, San Francisco. “Juno is at the forefront of an exciting new area of medicine that aims to leverage recent insights in immunology and cell therapy to create meaningfully better cancer treatments,” said Dr. Barron. “I look forward to working with Juno’s board and management team to continue to accelerate the pace and breadth of development of the company’s CAR and TCR technologies.”

About Juno

Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical company focused on revolutionizing medicine by re engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor (CAR) and high-affinity T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer. Juno has shown compelling efficacy in clinical trials using multiple cell-based product candidates to address refractory B cell lymphomas and leukemias. The company’s long-term aim is to improve and leverage its technologies to develop new product candidates that address a broader range of cancers and human diseases. Juno brings together innovative technologies from three of the world’s leading cancer centers – the Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, and Seattle Children’s Research Institute.

Contact: Morgan Warners, The Glover Park Group
mwarners@gpgdc.com, 202-295-0124

Juno Therapeutics today announced the close of its B round of financing with $134M in new investment.

By | News, Press Release

Total investment in the company now tops $300M in less than 12 Months

Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment.

This latest round includes new investments by ten public mutual funds and healthcare-focused funds. All major prior investors participated as well. The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.

Juno announced the close of its $176M Series A in April. Combining the A and B rounds, Juno has raised more than $300M in less than 12 months.

“Juno continues to make significant progress in developing new therapies with the potential to radically change the outlook for patients battling cancer,” said Hans Bishop, CEO of Juno. “We are delighted by the vote of confidence coming from new Series B investors and founding investors alike. Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies.”

Leerink Partners LLC acted as exclusive financial advisor in this transaction.

Juno Therapeutics launched in December 2013 and was co-founded with financial support from ARCH Venture Partners and the Alaska Permanent Fund through a partnership managed by Crestline Investors.
###

About Juno

Juno is a clinical stage company that brings together innovative technologies from three of the
world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan
Kettering Cancer Center and Seattle Children’s Research Institute – to advance a broad pipeline of
potential curative immunotherapy treatments. Juno will build on breakthroughs in the design of
novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen
receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell
surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology
can also detect alterations in intracellular proteins present in tumor cells. These treatments have
the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno’s
goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA
licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Contact: Alissa Brenner, The Glover Park Group
abrenner@gloverparkgroup.com, 202-295-0121

Juno Scientific Founders Receive NYIPLA Inventor of the Year Award

By | News, Press Release

Drs. Michel Sadelain, Renier J. Brentjens of Memorial Sloan Kettering Cancer Center recognized for CARs research

Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today congratulated two of its scientific founders, Drs. Michel Sadelain and Renier J. Brentjens of Memorial Sloan Kettering Cancer Center, for winning the esteemed New York Intellectual Property Law Association (NYIPLA) “Inventor of the Year” award. Sadelain and Brentjens were recognized for their extensive work in the design of chimeric antigen receptors (CARs), a significant part of Juno’s therapeutic platform. Data from their clinical trials has demonstrated the capacity of CAR-modified T cells to eradicate chemotherapy-resistant leukemias.

“We are delighted that the NYIPLA is honoring Dr. Sadelain and Dr. Brentjens,” said Hans Bishop, CEO of Juno. “Michel and Renier have dedicated years to unlocking the potential of CAR T cells. Their work has the potential to transform how we treat cancer.”

Juno will build on breakthroughs such as those by Drs. Sadelain and Brentjens in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs).

The award was presented on May 20 at the 2014 NYIPLA annual meeting at the Princeton Club of New York.
###

Dr. Michel Sadelain

Dr. Michel Sadelain is Head of the Gene Transfer and Gene Expression Laboratory at Memorial Sloan Kettering Cancer Center (MSKCC). Dr. Sadelain’s research focuses on T cell engineering as a means to eradicate cancer by targeting T cells and enhancing their function. His clinical program focuses on B cell malignancies as well as solid tumors. Dr. Sadelain is the incumbent of the Stephen and Barbara Friedman Chair and the founding director of the Center for Cell Engineering at MSKCC. He previously served on the board of directors of the American Society of Gene Therapy (2004-2007), of which he presently the Vice-President, and continues to serve on the editorial boards of Molecular Therapy, Human Gene Therapy and Gene Therapy.

Dr. Renier Brentjens

Dr. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed residency in medicine at Yale-New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). Currently, Dr. Brentjens is an associate member on the faculty at MSKCC and an attending physician on the Leukemia Service. As a medical oncology fellow at MSKCC, Dr. Brentjens initiated the initial pre-clinical studies demonstrating the potential clinical application of autologous T cells genetically modified to target the CD19
antigen through the retroviral transfer of artificial T cell receptors termed chimeric antigen receptors (CARs).

About Juno

Juno is a clinical stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno’s goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Contact:
Alissa Brenner, The Glover Park Group
abrenner@gloverparkgroup.com, 202-295-0121

Juno Completes $176M Series A Round

By | News, Press Release

Leading Cancer Immunotherapy Startup also Bolsters Leadership Team with Two Key Appointments

Juno Therapeutics, a biotechnology company focused on bringing
forward novel immunotherapies for cancer, today announced the close of its Series A round
with $176M in fully committed funds.

Juno’s initial funding of $120 million came predominantly from leading technology venture
capital firm ARCH Venture Partners and the Alaska Permanent Fund, through a partnership
managed by Crestline Investors. The completion of the A round includes expansions from
founding investors as well as investments from Bezos Expeditions, the personal investment
company of Jeff Bezos, and Venrock, amongst others.

“Juno’s Series A round provides significant resources to support truly transformative science,”
said Hans Bishop, CEO of Juno. “Juno’s approach to cancer immunotherapy brings together
world-class clinical, business and regulatory skills necessary to make a game changing impact
on cancer treatment. We couldn’t be more thankful for the enthusiasm and support Juno is
generating.”

In addition, Juno announced two major appointments to its leadership team.

Mark W. Frohlich, M.D., has been appointed to Executive Vice President of R&D. In this role he
will oversee the company’s scientific, clinical and regulatory activities.

Barney Cassidy will serve as General Counsel. He will lead Juno’s legal affairs including
corporate, intellectual property, litigation and compliance matters.

“These appointments come at an exciting time for Juno,” said Bishop. “I am delighted to have
the benefit of Mark and Barney’s capable leadership.”

Dr. Frohlich stated, “Immunotherapy is transforming the practice of oncology. I am incredibly
excited to join the outstanding team at Juno to advance its pipeline of highly promising cellular
therapies for cancer.”

“I admire both the scientific breakthroughs of Juno’s investigators and the compelling vision of
Juno’s founders,” said Barney Cassidy. “I’m really looking forward to working with the entire
team to develop, commercialize, and make widely available cancer therapies that emerge from
these extraordinary breakthroughs.”

Bios

Dr. Mark W. Frohlich, M.D. has more than two decades of experience in the field of immuno-oncology. He recently served as the Executive Vice President of R&D and Chief Medical Officer of Dendreon Corp., where he led teams responsible for the U.S. and European approval of Provenge, the first FDA licensed active cellular immunotherapy for cancer. Prior to joining Dendreon, he served as Vice President of Xcyte Therapies, where he pursued the development of an autologous T-cell therapy for cancer. Dr. Frohlich is a board-certified medical oncologist. He received his M.D. from Harvard Medical School and did his post-doctoral training in Internal Medicine and Oncology at the University of California, San Francisco. He subsequently served on the faculty there, where he was active in translational and clinical research. He has a B.S. from Yale University in Electrical Engineering and Economics.

Bernard J. “Barney” Cassidy received his J.D. from Harvard Law School, where he was an editor of the Harvard Law Review and a research assistant to Professor Arthur R. Miller, focusing on Federal Practice and Procedure. After law school Mr. Cassidy clerked for the Honorable John T. Noonan, Jr. of the U.S. Court of Appeals for the Ninth Circuit. He later practiced law at both Skadden, Arps, Slate, Meagher & Flom and at Wilson, Sonsini, Goodrich & Rosati, where on a pro bono basis he led the medical and mental health elements of a class action on behalf of Pelican Bay State Prison inmates that successfully challenged the constitutionality of prison conditions and practices in the landmark case of Madrid v. Gomez, 889 F.Supp. 1146 (N.D. Cal. 1996). Mr. Cassidy later served as general counsel of two public companies, Tumbleweed Communications Corp., a provider of secure messaging and secure file transfer solutions, and Tessera Technologies, Inc., a semiconductor technology licensing company, where he was President of Tessera Intellectual Property Corp. He is a nationally recognized expert on patent licensing and patent policy, having testified twice on these topics before Congress, and is frequently invited to speak about the perspective of inventors within our innovation economy, at, for example, the joint workshop on patent and competition policy held by the U.S. Federal Trade Commission, U.S. Department of Justice, and the U.S. Patent & Trademark Office, and most recently at the 2014 Judicial Conference of the U.S. District Court for the Northern District of California.
###

About Juno

Juno is a clinical stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno’s goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Contact:
Alissa Brenner, The Glover Park Group
abrenner@gloverparkgroup.com, 202-295-0121

Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr as CFO and Head of Corporate Development

By | News, Press Release

Morgan Stanley’s Head of Global Biotech Investment Banking Joins Leading Cancer Immunotherapy Startup

Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today that Steve Harr, M.D., will join the company as its Chief Financial Officer and Head of Corporate Development.

Harr currently serves as Managing Director and Head of Biotechnology Investment Banking at Morgan Stanley. Prior to his investment banking role at Morgan Stanley, Harr was the firm’s biotech research analyst and co-head of global healthcare research, where he was consistently ranked as one of the top biotech analysts in the industry. He joins Juno after 12 years with Morgan Stanley, having managed more than $20 billion in financing deals and more than $40 billion in M&A transactions as well as spending many years interacting with institutional investors as a research analyst.

“We are delighted to have Steve join the team,” said Hans Bishop, CEO of Juno Therapeutics. “Steve joins Juno after its successful public launch and unprecedented Series A. We are thrilled to have his unmatched insights into the biotechnology industry and corporate finance and as we continue to grow and develop.”

In his new role, Harr will lead the development of Juno’s financing strategy and approach to broader strategic business relationships.

“Juno is a unique combination of strong science, world-class researchers and a stellar leadership team,” said Harr. “Like many people, I have family and friends who have been impacted by cancer. The opportunity to work at a company that has the potential to alter the course of treating this disease is highly attractive. I am excited to join the company and help make Juno’s therapies into a reality for patients.”

Prior to Morgan Stanley, Harr worked as a research analyst at Robertson Stephens. He obtained a BA in Economics from College of the Holy Cross and an M.D. from The Johns Hopkins University School of Medicine. He was an Internal Medicine resident at the University of California, San Francisco and performed research at Harvard Medical School and Massachusetts General Hospital, where he was an author on multiple published papers. Harr and his family will relocate to Seattle from New York.
###

About Juno

Juno is a clinical stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. With one of the largest ever Series A investments for a biotech startup, Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno’s goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Contact:
Alissa Brenner, The Glover Park Group
abrenner@gloverparkgroup.com, 202-295-0121

Juno Announces New Investments, Leadership Appointments

By | News, Press Release

Juno CEO Hans Bishop to Address JP Morgan’s 32nd Annual Healthcare Conference

Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A including Bezos Expeditions, the personal investment company of Jeff Bezos, and leading venture capital firm Venrock. The total Series A will exceed $145M.

Juno also announced new leadership appointments today. Marc Tessier-Lavigne, Ph.D., Anthony B. Evnin, Ph.D., and Howard H. Pien will join the company’s Board of Directors. José Baselga, M.D., Ph.D. will serve as chairman of Juno’s Clinical Advisory Board.

“This is an exciting time for Juno,” said Hans Bishop, CEO. “The investments from Bezos Expeditions and Venrock will help accelerate our growth as we work to transform how we treat cancer.”

Bishop continued, “We are delighted that Marc, Tony, Howard and José have agreed to lend their experience and expertise to Juno. Their leadership in the biotech and pharmaceutical sectors will serve Juno well in the years ahead.”

Bishop will address the audience of global health care and investment leaders at the JP Morgan Annual Healthcare Conference on Tuesday, January 14 at 9 a.m. in Elizabethan D at the Westin St. Francis Hotel in San Francisco.

Marc Tessier-Lavigne, Ph.D., is President of The Rockefeller University in New York City, which he joined in 2011. Previously, he served as Executive Vice President and Chief Scientific Officer at Genentech, Inc., after holding faculty positions at Stanford University and the University of California, San Francisco. A Rhodes Scholar, Dr. Tessier-Lavigne is a member of the National Academy of Sciences and its Institute of Medicine and a fellow of the Royal Societies of the United Kingdom and Canada. He is currently a Director of Agios Pharmaceuticals, Inc., Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.

Anthony B. Evnin, Ph.D., is a Partner of Venrock, a venture capital firm, which he joined in 1974. He is currently a Director of Acceleron Pharma, Inc., AVEO Pharmaceuticals, Inc. and Infinity Pharmaceuticals, Inc. as well as Constellation Pharmaceuticals, Inc., a private company. He serves as a Trustee of The Rockefeller University, as a Trustee of The Jackson Laboratory, as a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center, as a Member of the Board of Directors of the New York Genome Center, as a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and as a Trustee Emeritus of Princeton University.

Howard H. Pien has worked in the pharmaceutical and biotechnology industries for more than 30 years. From 2007 to 2009 he was the Chairman and CEO of Medarex Inc., until it was acquired by BMS and was Chairman and CEO of Chiron from 2003-2006. He currently serves as a Director on the Boards of Viropharma (as Lead Independent Director), Vanda (as Non-Executive Chairman), Immunogen, and Ikaria. He is also an advisor to the Life Sciences Practice of Warburg Pincus.

Dr. Tessier-Lavigne, Dr. Evnin and Mr. Pien join Juno business co-founders Larry Corey, M.D., president and director of Fred Hutchinson Cancer Research Center, Richard Klausner, M.D., Senior Vice President and Chief Medical Officer of Illumina Corporation, Robert Nelsen, co-founder and a Managing Director of ARCH Venture Partners, and Hans Bishop, CEO, Juno Therapeutics on the board of directors.

José Baselga, M.D., Ph.D., is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center. Dr. Baselga was previously Chief of Medical Oncology at Massachusetts General Hospital in Boston, Massachusetts (USA), Associate Chief of the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School. Prior to that he was Chairman and Professor of Medicine of Medical Oncology Service at the Vall d’Hebron University Hospital in Barcelona, Spain. He is a prominent member of the American Association for Cancer Research (AACR) and has published over 250 publications in major peer reviewed journals.

The Fred Hutchinson Cancer Research Center (Fred Hutch) and Memorial Sloan-Kettering Cancer Center (MSKCC), along with pediatric partner Seattle Children’s Research Institute, joined forces to launch Juno Therapeutics in December 2013. Juno launched with an initial investment of $120M, making it one of the largest Series A biotech startups in history. For more information please visit www.junotherapeutics.com.
###

About Juno

Juno is a clinical stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of potential curative immunotherapy treatments. With one of the largest ever Series A investments for a biotech startup, Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. Juno’s goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Contact:
Alissa Brenner, The Glover Park Group
abrenner@gloverparkgroup.com, 202-295-0121